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greater susceptibility to invasive aspergillosis. T-cell secreted cytokine
response to aspergillus antigen in culture may be used to predict
patients’ ability to generate an immune response or can be associated
with disease progression. The production of -IFN is associated with
Th1 cell mediated immunity and results in greater resistance to
antigens. Production of Th2 cytokines, IL-10 and IL-4, indicates
immunosuppression and tolerance. T-cell secreted cytokines can be
detected using conventional enzyme-linked immunoassay (ELISA)
technology. The cytokine proﬁle produced during culture with as-
pergillus antigen may provide useful information on a patients ability
to mount an immune response to this speciﬁc antigen. Method: A.
fumigatus conidia were inoculated into Sabourad broth and incubated
for 42hours under appropriate conditions. The mycelial mat formed
was washed, disrupted with a homogenizer and cellular extract col-
lected. Protein content was determined using BSA standard. Antigen
was cultured initially with Ficolled mononuclear cells (MNCs) from
healthy normal donors to determine the minimum dose resulting in
best cytokine response. MNCs from patients at 3 and 6 month time
points after unrelated allogeneic transplantation were cultured withA.
fumigatus antigen at a concentration of 1  106 cells/ml. Cultures
were incubated at 37°C with 5% CO2 for 16-24 hours, centrifuged,
supernatant removed and frozen at 70°C until testing. IL-2, IL-4,
IL-10 and -IFN 96 well plate ELISA assays were performed on
thawed supernatants. Results: In patients who had undergone allo-
geneic transplants, 22 of 30 (73%) had higher IL-10/-IFN ratios
(34.0; range 0.03-486.7) at 3 months post transplant. In contrast, at 6
months, 8 of 14 (57%) had a higher IL-10/-IFN ratio (27.1; range
0.03-217.8). IL-2 secretion was undetectable in all 3 and 6 month post
transplant samples. Conclusions: Higher IL-10/-IFN ratios in pa-
tients at 3 months post-allogeneic transplant suggests a Th2 or more
immunosuppressive response to aspergillus. At 6 months post-trans-
plant, the average IL-10/-IFN ratio decreases which suggests an
increase in the number of patients able to demonstrate a Th1 cell
mediated immune response to A. fumigatus.
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DISEASE STATUS AT TRANSPLANT IMPACTS LYMPHOCYTE AND PLATE-
LET RECOVERY AFTER ALLOGENEIC PERIPHERAL BLOOD STEM CELL
TRANSPLANT (PBSCT) FOR PATIENTS WITH AML/MDS
Saliba, R.M.1, Oran, B.1, Giralt, S.1, Komanduri, K.1,
Carrasco-Yalan, A.2, Ghosh, S.1, Champlin, R.1, de Lima, M.1 1.
Department of Blood and Marrow Transplantation, U.T. M.D. Ander-
son Cancer Center, Houston, TX; 2. CECLA, Mexico.
Lymphocyte and platelet count have been correlated with outcomes
of allogeneic SCT. We sought to test this hypothesis in a homoge-
neous group of patients with AML/MDS. Patients andMethods: 54
consecutive patients with high-risk AML/MDS received a matched-
sibling PBSCT with ﬂudarabine (100-180 mg/m2) and melphalan
(100-180mg/m2) conditioning and tacrolimus-basedGVHDprophy-
laxis between 1996 and 2003. Median age was 55 years (23-68).
Disease status at PBSCT was complete remission (CR, 15/54), No
CR with (NoCR/CB, 15/54) or without circulating blasts (NoCR/
NoCB, 24/54). Cytogenetics were high-risk in 45% of patients, in-
termediate in 46%, unknown in 9%. Cox’s regression analysis was
used to evaluate predictors of outcome at landmarks starting at day 30
post-SCT. We evaluated day 30 lymphocyte and platelet count (cat-
egorized at the respectivemedians: 760 109/L and 80 109/L), age,
cytogenetics, disease status at transplant, ﬁrst remission duration, and
grade II-IV acute GVHD (a-GVHD) and chronic GVHD as time-
dependent variables.Results: 51/54 patients were alive by day 30, and
47/51 (92%) had achieved a CR; 40/44 patients tested achieved 100%
donor chimerism. Actuarial survival for these 47 patients in CR was
51% and disease progression 36% at 3 years. Grade II-IV a-GVHD
was the only signiﬁcant predictor of mortality at 3 years (HR  2.8,
P .02). Disease status of NoCR/CB at PBSCT (HR 2.3, 95% CI
0.9-6), lymphocyte (HR  1.8, 95% CI 0.8-4) and platelet count
below the median (HR  1.6, 95% CI 0.7-4) showed a trend for
higher mortality. Disease status of NoCR/CB at PBSCTwas the only
signiﬁcant predictor of disease progression (HR  4.6, P  .003).
Lymphocyte count below the median showed a trend for higher
progression rate (HR  2.8, 95% CI (0.96-8)), in contrast to low
platelet count (HR 1.1 (95%CI 0.4-3)). A stratiﬁed analysis showed
that patients who were in CR at PBSCT achieved the highest count
on average, followed by the NoCR/NoCB and the NoCR/CB groups
(Table 1). A similar pattern was observed excluding patients diagnosed
with a-GVHD by day 30, or stratifying by the dose of melphalan in
the preparative regimen. Conclusion: Among patients in CR after
PBSCT for AML/MDS, day 30 lymphocyte and platelet counts are
highly correlated with disease status at PBSCT. This illustrates the
limited usefulness of these variables as independent predictors of
outcome and highlights theassociation of disease status at PBSCT and
delayed early lymphoid reconstitution (Table 1).
Table 1. Lymphocyte and Platelet Count (109/L) on Day 30 post
Transplant for Patients Who Were in CR at That Time According to
Disease Status at the Time of Transplant
CR
(n  15)
*No CR/No
CB
(n  19)
*No
CR/CB
(n  13)
Test for
Trend
(P Value)
Median
lymphocyte
count (range)
1010 (230–1770) 760 (220–3500) 470 (70–1820) .10
Median platelet
count (range)
114 (16–64) 75 (21–189) 61 (11–279) .03
Days to platelet
count 20K
(range)
14 (10–24) 15 (7–72) 22 (10–72) .01
Excluding patients
with a-GVHD
by day 30
n  11 n  15 n  8
Median
lymphocyte
count (range)
1030 (380–1770) 770 (260–3500) 560 (70–119) .03
Median platelet
count (range)
114 (56–164) 85 (21–189) 53 (31–121) .04
*CR: complete remission, CB: circulating blast.
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NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (NMT) IS WELL TOLERATED AND EFFECTIVE IN ASIAN PATIENTS
WITH HIGH RISK HEMATOLOGICAL MALIGNANCIES
Chen, C.-S.1,2, Yusof, N.2, Tan, B.2, Law, P.1,2, Soh, T.G.2, Yasir, F.2,
Tan, L.K.2 1. National University of Singapore, Singapore, Singapore;
2. National University Hospital, Singapore, Singapore.
Aims:To evaluate the safety and feasibility of NMT for high risk
diseases in Asian patients excluded from conventional allogeneic
transplant due to co-morbidity, we initiated an IRB-approved pro-
tocol adapting published conditioning regimen with ﬂudarabine
(day 4 to 2, total 90 mg/m2) and TBI (day 0, 200 cGy).
However, GVHD prophylaxis was modiﬁed with the combination
of cyclosporin, mycophenolate mofetil and methotrexate (day 1, 3,
6, and 11). IVIG was given bi-weekly until day 100. Methods: 13
eligible patients with matched sibling donors (10/3 M/F) enrolled
with median age 42 (range: 19-62). Peripheral blood stem cells
were collected after G-CSF mobilization. Diseases included my-
elodysplastic syndrome (MDS-RA and RAEBT) (n  5), multiple
myeloma (MM) (4), acute myeloid leukemia (AML) (3) and chronic
myeloid leukemia (CML) (1). Among 5 MDS, one MDS-RA pa-
tient had end stage renal failure (IgA nephropathy) on daily peri-
toneal dialysis and one had aplastic marrow not recovering after
initial induction chemotherapy. All MM patients had failed previ-
ous autologous transplants with one failed both autologous and
allogeneic transplants. Among AML patients, one had compro-
mised cardiac function unable to complete induction chemother-
apy; one had chronic hepatitis, and one with transformed AML
who did not have consolidation chemotherapy prior to transplant.
Results: A median dose of 4.71  106 CD34 cells/kg (3.05-8.15)
and 3.69  108 CD3 T cells/kg (1.85-8.12) was infused after
conditioning. Absolute neutrophil counts fell below 500/l for all
except one patient and the median duration of neutropenia was 14
days (0-20). Only 4 patients experienced thrombocytopenia (plate-
let 20000/l) and required transfusions of 2 units (median, range
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